Filiz Oezkan depicts the most important factors influencing the choice of treatment in patients with PD-L1-positive NSCLC, explains how the 50 % PD-L1 threshold affects the treatment selection and explains which treatment options appear favorable in the setting of PD-L1 levels below 1 % while also taking into account possible challenges associated with biomarker testing for PD-L1 in NSCLC.

Here is the full WCLC 2022 report.